Takeda Pharmaceuticals will collaborate with Numerate, a computational drug design company, on a new drug development initiative, reports GEN.
Numerate will use its artificial intelligence platform to help Takeda identify and develop new drug candidates in three core therapeutic areas: oncology, gastroenterology and central nervous system disorders.
Takeda will pay Numerate an undisclosed amount of milestone payments and royalties through the multiyear agreement.
"By having Numerate select projects that align with Takeda's strategy, we expect the partnership to yield multiple assets that Takeda can develop into truly transformative medicines for patients," David Weitz, head of Takeda California and Global Research Externalization, told GEN.
More articles on supply chain:
Top pharmacist-recommended health products for 2017
EpiPen scandal grounds for removal of Mylan board members, says advisory firm
Haylard Health eyes sale of surgical, infection prevention unit